The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Seminars in Cancer Biology

• Publication date

  2015-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.semcancer.2015.08.006PMID 26304731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

  2016cited by this paper
• Nachweis von zellfreier lncRNA im Serum von Tumorpatienten

  2015cited by this paper
• Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.

  2015cited by this paper
• Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

  2015cited by this paper
• Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors

  2015cited by this paper
• The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC + bevacizumab.

  2015cited by this paper
• Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer.

  2015cited by this paper
• Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.

  2015cited by this paper
• A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

  2015cited by this paper
• Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

  2014cited by this paper
• The Promise of Novel Molecular Markers in Bladder Cancer

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity

  2014cited by this paper
• Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

  2014cited by this paper
• Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis

  2014cited by this paper
• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

  2014cited by this paper
• A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

  2014cited by this paper
• Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies

  2014cited by this paper
• Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors.

  2014cited by this paper
• Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

  2014cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• Using microRNA profiling in urine samples to develop a non‐invasive test for bladder cancer

  2013cited by this paper
• Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

  2013cited by this paper
• Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation

  2013cited by this paper
• Toward a molecular pathologic classification of urothelial carcinoma.

  2013cited by this paper
• Urinary markers for bladder cancer

  2013cited by this paper
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

  2012cited by this paper
• The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes

  2012cited by this paper
• p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers

  2012cited by this paper
• Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma.

  2012cited by this paper
• Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.

  2012cited by this paper
• Genome Sequencing Identifies a Basis for Everolimus Sensitivity

  2012cited by this paper
• Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.

  2012cited by this paper
• A Molecular Taxonomy for Urothelial Carcinoma

  2012cited by this paper
• A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges

  2012cited by this paper
• Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

  2012cited by this paper
• CDKN2A homozygous deletion is associated with muscle invasion in FGFR3‐mutated urothelial bladder carcinoma

  2012cited by this paper
• Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

  2011cited by this paper
• Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.

  2011cited by this paper
• Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.

  2011cited by this paper
• Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma

  2011cited by this paper
• International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

  2011cited by this paper
• Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

  2010cited by this paper
• Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

  2010cited by this paper
• Inhibiting the Hypoxia Response for Cancer Therapy: The New Kid on the Block

  2009cited by this paper
• Occupation and cancer – follow-up of 15 million people in five Nordic countries

  2009cited by this paper
• T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival

  2008cited by this paper
• Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

  2008cited by this paper
• Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis

  2008cited by this paper
• PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata

  2007cited by this paper
• A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

  2007cited by this paper
• Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

  2007cited by this paper
• Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

  2007cited by this paper
• CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

  2007cited by this paper
• Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

  2006cited by this paper
• Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.

  2006cited by this paper
• Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

  2006cited by this paper
• Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

  2005cited by this paper
• Lessons learned in the surgical management of renal cell carcinoma.

  2005cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Molecular pathogenesis of urothelial bladder cancer.

  2003cited by this paper
• DNA alterations in body fluids as molecular tumor markers for urological malignancies.

  2002cited by this paper
• Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer.

  2002cited by this paper
• Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer.

  1992cited by this paper
• Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change

  1982cited by this paper

• Comparison of Cold-Cup Biopsy Versus Resection Biopsy in the Early Detection of Detrusor Muscle Invasion in the Case of Bladder Tumor

  2025cites this paper
• The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer.

  2023cites this paper
• Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy

  2022cites this paper
• Comprehensive genomic profiling of histologic subtypes of urethral carcinomas.

  2021cites this paper
• The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

  2021cites this paper
• Can serum matrix metalloproteinase‐9 and SMAD‐2 levels predict lamina propria invasion in bladder urothelial carcinoma?

  2021cites this paper
• A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer

  2021cites this paper
• HMGA2 Promotes Colorectal Cancer Angiogenesis via Dual Regulation of Sema3A and VEGFA

  2021cites this paper
• LncRNA HAND2-AS1 exerts anti-oncogenic effects on bladder cancer via restoration of RARB as a sponge of microRNA-146

  2020cites this paper
• Sex-Determining Region Y Chromosome-Related High-Mobility-Group Box 10 in Cancer: A Potential Therapeutic Target

  2020cites this paper
• Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data.

  2019cites this paper
• Implementing TMB measurement in clinical practice: considerations on assay requirements

  2019cites this paper
• circLPAR1 is a novel biomarker of prognosis for muscle-invasive bladder cancer with invasion and metastasis by miR-762.

  2019cites this paper
• Role of PRMT5 in bladder cancer: a comprehensive study

  2019cites this paper
• Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications

  2018cites this paper
• GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial–mesenchymal transition through the TGF‐β1/Smad2 signalling pathway

  2018cites this paper
• The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.

  2018cites this paper
• FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells

  2018cites this paper
• FOXO1: Another avenue for treating digestive malignancy?

  2017cites this paper
• Phosphatidylserine: A cancer cell targeting biomarker.

  2017cites this paper
• Urothelial cancer of the urinary bladder: can lessons learned be applied to the upper urinary tract?

  2016cites this paper
• Dictatorial streaming of biomarkers in some diseases

  2016cites this paper